Moving forward with metronomic chemotherapy: Meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology

Translational Oncology

Volumn 4, Issue 4, 2011, Pages 203-211

  Pasquier, Eddy ^a   Kieran, Mark W ^b   Sterba, Jaroslav ^c   Shaked, Yuval ^d   Baruchel, Sylvain ^e   Oberlin, Odile ^f   Kivivuori, Maria Sanna ^g   Peyrl, Andreas ^h   Diawarra, Mamouna ⁱ   Casanova, Michaela ^j   Zacharoulis, Stergios ^k   Vassal, Gilles ^f   Berthold, Franck ^l   Verschuur, Arnauld ^m   André, Nicolas ^m,n,o  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ HÔPITAL GABRIEL TOURÉ   (Mali)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^l UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^m TIMONE HOSPITAL   (France)

ⁿ AIX MARSEILLE UNIVERSITY   (France)

^o Metronomics Global Health Initiative   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; CYCLOPHOSPHAMIDE; ETOPOSIDE; FENOFIBRATE; IDARUBICIN; METHOTREXATE; NAVELBINE; RETINOIC ACID; TEMOZOLOMIDE; THALIDOMIDE; TROFOSFAMIDE; VALPROIC ACID; VINBLASTINE; VINCRISTINE; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BRAIN STEM; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHILDHOOD CANCER; CLINICAL TRIAL (TOPIC); EPENDYMOMA; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; LOW DRUG DOSE; MEDULLOBLASTOMA; NEUROBLASTOMA; OSTEOBLASTOMA; OSTEOSARCOMA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PONTINE GLIOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 79960303699     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11124     Document Type: Article

References (56)

1. Weitman SD, Glatstein E, and Kamen BA (1993). Back to the basics: the importance of concentration × time in oncology. J Clin Oncol 11, 820-821.
2. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, and Folkman J (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60, 1878-1886.
3. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, and Kerbel RS (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105, R15-R24.
4. Hanahan D, Bergers G, and Bergsland E (2000). Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105, 1045-1047.
5. Pasquier E, Kavallaris M, and Andre N (2010). Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7, 455-465.
6. Samuel DP, Wen PY, and Kieran MW (2009). Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs 18, 973-983.
7. Haim N, Ben-Shahar M, and Epelbaum R (1995). Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. Cancer Chemother Pharmacol 36, 352-355.
8. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, and Longee D (1996). Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14, 1922-1927.
9. Kieran MW and Billett A (2001). Antiangiogenesis therapy. Current and future agents. Hematol Oncol Clin North Am 15, 835-851, vii.
10. Andre N, Pasquier E, Gentet JC, and Kamen BA (2011). Looking at the seemingly contradictory role of vinblastine in anaplastic large-cell lymphoma from a metronomic perspective. J Clin Oncol 29, e90-e91.
11. Sterba J, Pavelka Z, and Slampa P (2002). Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 49, 117-120.
12. Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, et al. (2005). A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27, 573-581.
13. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M, Laforme AM, Chaponis DM, Folkman J, and Kieran MW (2008). PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 105, 985-990.
14. Panigrahy D, Kaipainen A, Butterfield CE, Chaponis DM, Laforme AM, Folkman J, and Kieran MW (2010). Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med 1, 739-746.
15. Peyrl A, Azizi AA, Reismueller B, Kieran MW, Heinrich M, Czech T, Dieckmann K, and Slavc I (2010). Antiangiogenic metronomic chemotherapy for patients with recurrent embryonal and ependymal brain tumors. Neuro-Oncol 12, ii44.
16. Sterba J, Valik D, Mudry P, Kepak T, Pavelka Z, Bajciova V, Zitterbart K, Kadlecova V, and Mazanek P (2006). Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 29, 308-313.
17. Klingebiel T, Boos J, Beske F, Hallmen E, Int-Veen C, Dantonello T, Treuner J, Gadner H, Marky I, Kazanowska B, et al. (2008). Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 50, 739-745.
18. Casanova M, Ferrari A, Spreafico F, Terenziani M, Massimino M, Luksch R, Cefalo G, Polastri D, Marcon I, and Bellani FF (2002). Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 94, 3263-3268.
19. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, Tettoni K, Provenzi M, Mazzarino I, and Carli M (2004). Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101, 1664-1671.
20. Kivivuori SM, Riikonen P, Valanne L, Lonnqvist T, and Saarinen-Pihkala UM (2011). Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas. Acta Paediatr 100, 134-138.
21. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, and Baruchel S (2006). A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 28, 720-728.
22. Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez CV, and Bouffet E (2006). Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42, 2335-2342.
23. Sharp JR, Bouffet E, Stempak D, Gammon J, Stephens D, Johnston DL, Eisenstat D, Hukin J, Samson Y, Bartels U, et al. (2010). A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J Cancer 46, 3271-3279.
24. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, et al. (2008). Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 26, 399-405.
25. Russel HV, Groshen SG, Ara T, Declerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, et al. (2010). A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer, E-pub ahead of print.
26. Fousseyni T, Diawara M, Pasquier E, and André N (2011). Children treated with metronomic chemotherapy in a low-income country:METRO-MALI-01. J Pediatr Hematol Oncol 33, 31-34.
27. Kellie SJ and Howard SC (2008). Global child health priorities: what role for paediatric oncologists? Eur J Cancer 44, 2388-2396.
28. Klement GL and Kamen BA (2011). Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? J Pediatr Hematol Oncol 33, 1-3.
29. Gasparini G (2001). Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2, 733-740.
30. Andre N, Padovani L, and Pasquier E (2011). Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol 7, 385-394.
31. Andre N, Rome A, Coze C, Padovani L, Pasquier E, Camoin L, and Gentet JC (2008). Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clin Ther 30, 1336-1340.
32. Lopez-Aguilar E, Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Rocha-Moreno YG, Gascon-Lastiri G, Rivera-Marquez H, Wanzke-del-Angel V, Cerecedo-Diaz F, and de la Cruz-Yanez H (2008). Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children. Arch Med Res 39, 655-662.
33. le Deley MC, Vassal G, Taibi A, Shamsaldin A, Leblanc T, and Hartmann O (2005). High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer 45, 25-31.
34. Ridola V, Fawaz O, Aubier F, Bergeron C, de Vathaire F, Pichon F, Orbach D, Gentet JC, Schmitt C, Dufour C, et al. (2009). Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamidebased regimens. Eur J Cancer 45, 814-818.
35. Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai SR, Arbeit JM, Voest EE, Chaplin DJ, et al. (2009). Contribution of granulocyte colonystimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 69, 7524-7528.
36. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, et al. (2008). Rapid chemotherapyinduced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14, 263-273.
37. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, et al. (2006). Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785-1787.
38. Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, and Kerbel RS (2009). Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 8, 2872-2881.
39. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, and Kerbel RS (2007). Multiple circulating proangiogenic factors induced by sunitinib malate are tumorindependent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104, 17069-17074.
40. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, and Kerbel RS (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239.
41. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, and Casanovas O (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231.
42. Bertolini F, Shaked Y, Mancuso P, and Kerbel RS (2006). The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6, 835-845.
43. Pasquier E and Dias S (2010). Endothelial progenitor cells: hope beyond controversy. Curr Cancer Drug Targets 10, 914-921.
44. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, and Kerbel RS (2005). Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106, 3058-3061.
45. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, et al. (2005). Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7, 101-111.
46. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, et al. (2006). Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108, 452-459.
47. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, et al. (2008). Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26, 4899-4905.
48. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, et al. (2009). Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15, 7652-7657.
49. Kerbel RS (2006). Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171-1175.
50. Shaked Y and Kerbel RS (2007). Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 67, 7055-7058.
51. Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, and Zitvogel L (2007). Links between innate and cognate tumor immunity. Curr Opin Immunol 19, 224-231.
52. Choijamts B, Naganuma Y, Nakajima K, Kawarabayashi T, Miyamoto S, Tachibana K, and Emoto M (2011). Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft. Cancer Sci 102, 452-459.
53. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, et al. (2009). Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8, 1596-1603.
54. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, and Kerbel RS (2011). Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13, 40-48.
55. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM, and Kerbel RS (2009). Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69, 7243-7251.
56. Sterba J, Pavelka Z, Andre N, Ventruba J, Skotakova J, Bajciova V, Bronisova D, Dubska L, and Valik D (2010). Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatr Blood Cancer 54, 616-617.